This company has been marked as potentially delisted and may not be actively trading. Cogent Biosciences (UMRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock UMRX vs. CALT, ZYME, SBTX, MBX, AVTE, PTN, NLTX, CYBN, BIOA, and VIRIShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Palatin Technologies (PTN), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), and Virios Therapeutics (VIRI). Cogent Biosciences vs. Its Competitors Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Palatin Technologies Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Cogent Biosciences (NASDAQ:UMRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation. Do institutionals and insiders have more ownership in CALT or UMRX? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 26.4% of Cogent Biosciences shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 31.5% of Cogent Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, CALT or UMRX? Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 3.93, suggesting that its stock price is 293% more volatile than the S&P 500. Does the media refer more to CALT or UMRX? In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Cogent Biosciences'average media sentiment score. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Cogent Biosciences Neutral Is CALT or UMRX more profitable? Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Cogent Biosciences' net margin of -96.84%. Cogent Biosciences' return on equity of -87.78% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Cogent Biosciences -96.84%-87.78%-52.14% Which has higher valuation and earnings, CALT or UMRX? Cogent Biosciences has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Cogent Biosciences$22.50M22.88-$31.83M-$1.04-11.65 SummaryCogent Biosciences beats Calliditas Therapeutics AB (publ) on 8 of the 11 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UMRX vs. The Competition Export to ExcelMetricCogent BiosciencesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$514.72M$833.52M$5.81B$9.76BDividend YieldN/A4.84%4.40%4.06%P/E Ratio-15.951.1831.3026.05Price / Sales22.88152.90387.2688.36Price / CashN/A19.5638.0259.36Price / Book11.656.649.536.60Net Income-$31.83M-$4.94M$3.26B$265.65M Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UMRXCogent BiosciencesN/A$12.12+3.0%N/A+19.1%$514.72M$22.50M-15.9572CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks1.7971 of 5 stars$13.94+7.1%$21.43+53.7%+32.6%$1.05B$122.87M-9.29460SBTXSilverback TherapeuticsN/A$16.66+1.7%N/A+4.2%$600.73MN/A-6.8883Positive NewsHigh Trading VolumeMBXMBX Biosciences1.9568 of 5 stars$12.95+3.4%$37.63+190.5%N/A$435.04MN/A-2.8536AVTEAerovate TherapeuticsN/A$7.39-0.1%N/A-87.4%$214.20MN/A-2.4720High Trading VolumePTNPalatin TechnologiesN/A$7.20+7,551.4%N/AN/A$187.24M$350K-4.6530Gap UpNLTXNeoleukin TherapeuticsN/A$19.22-5.6%N/A-42.8%$180.63MN/A-6.1890High Trading VolumeCYBNCybin2.417 of 5 stars$7.60-0.4%$85.00+1,018.4%N/A$179.28MN/A-1.7350News CoverageAnalyst RevisionBIOABioAge LabsN/A$4.56+1.8%N/AN/A$163.48M$3.86M0.00N/AVIRIVirios TherapeuticsN/A$4.85+1.7%$5.00+3.1%+2,250.8%$93.40MN/A-17.965Gap Up Related Companies and Tools Related Companies CALT Alternatives ZYME Alternatives SBTX Alternatives MBX Alternatives AVTE Alternatives PTN Alternatives NLTX Alternatives CYBN Alternatives BIOA Alternatives VIRI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UMRX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access